ArticleInternational ophthalmology2026
Safety and efficacy of contact lens-assisted accelerated corneal cross-linking using Nelfilcon A in thin corneas.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy and safety of contact lens-assisted accelerated corneal cross-linking (A-CACXL) using a UV-filter-free nelfilcon A daily hydrogel lens in thin corneas (≤ 400 µm).
methodsRetrospective single-center series of 28 eyes (23 patients) with progressive keratoconus and post-debridement pachymetry ≤ 400 µm; minimum follow-up 6 months. A-CACXL employed a 100-µm nelfilcon A lens. Outcomes at Baseline, Month 1, Month 3, and Month 6 included UCVA/BCVA (logMAR), refraction, K1, K2, Kmean, Kmax (D), minimum corneal thickness (MCT, µm), and endothelial cell count (ECC, cells/mm
resultsBCVA improved significantly (p = 0.005), whereas UCVA showed a non-significant favorable trend (p = 0.246). K2 and Kmean decreased over time (p < 0.001 and p < 0.001), and Kmax decreased with Greenhouse-Geisser correction (p = 0.033); K1 remained stable (p = 0.233). MCT demonstrated an early thinning at Month 1 and Month 3 with partial rebound by Month 6 (omnibus p < 0.001; Bonferroni-significant vs Baseline). Manifest cylinder decreased modestly (p = 0.048), whereas manifest sphere was unchanged (p = 0.495). ECC remained stable across visits (p = 0.124). Adverse events were limited to transient, clinically insignificant haze in 2/28 eyes (7.1%), resolving by Month 3. All eyes satisfied the intraoperative functional thickness ≥ 400 µm threshold.
conclusionsA-CACXL with a nelfilcon A lens appears to be a pragmatic, safe, and effective option for thin corneas, yielding early BCVA improvement, modest anterior flattening, and preserved endothelium through six months.
Indexed as
Identifiers
41591605What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.